BusinessMelinta Therapeutics Publishes Complete Results from Phase 3 TANGO I Study of VABOMERE™ (meropenem and vaborbactam) in Patients with cUTIBy Nasdaq OMXFeb 27, 2018, 9:05 PM UTC
BusinessMelinta Therapeutics Enters Into Agreement to Acquire Infectious Disease Business from The Medicines CompanyBy Nasdaq OMXNov 29, 2017, 12:00 PM UTC
